Microbicides Acceptability Among Sexually Active Young Women
Microbicide-Use Adherence, Acceptability, and Attitudes Among Sexually Active Young Women Participating in a Phase I Microbicide Trial (MTN 004) "Tell Juliana"
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00936
- University Pediatric Hospital
-
-
-
-
Florida
-
Tampa, Florida, United States, 33606
- University of South Florida College of Medicine
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Currently enrolled in MTN 004.
- Willing and able to provide written informed consent for ATN 062.
- Willing to participate as required by protocol, including completion of all assessments and follow-ups.
Exclusion Criteria:
- Refuses to have teleconferences audio recorded.
- Any social or medical condition that, in the investigator's opinion, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
1
Participants use Vivagel™, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
|
Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial.
They will have three teleconferences with "Juliana" to discuss the product and the technology used in the study.
They will also have the opportunity to send emails to "Juliana" during the course of the study.
Other Names:
|
|
2
Participants use VivaGel™ Placebo, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
|
Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial.
They will have three teleconferences with "Juliana" to discuss the product and the technology used in the study.
They will also have the opportunity to send emails to "Juliana" during the course of the study.
Other Names:
|
|
3
Participants use HEC Placebo Gel (HEC Gel), applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
|
Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial.
They will have three teleconferences with "Juliana" to discuss the product and the technology used in the study.
They will also have the opportunity to send emails to "Juliana" during the course of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Microbicide use adherence as measured by a computerized phone diary
Time Frame: 21 days(through end of study)
|
21 days(through end of study)
|
|
Microbicide use adherence as measured by e-mail messages
Time Frame: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use adherence as measured by in-depth interviews via teleconference
Time Frame: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use acceptability as measured by a computerized phone diary
Time Frame: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use acceptability as measured by e-mail messages
Time Frame: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use acceptability as measured by in-depth interviews via teleconferences
Time Frame: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use attitudes as measured by a computerized phone diary
Time Frame: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use attitudes as measured by e-mail messages
Time Frame: 21 days (through end of study)
|
21 days (through end of study)
|
|
Microbicide use attitudes as measured by in-depth interviews via teleconferences
Time Frame: 21 days (through end of study)
|
21 days (through end of study)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Alex Carballo-Diéguez, PhD, HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ATN 062
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.